Bortezomib-thalidomide-dexamethasone is superior to
thalidomide-dexamethasone as consolidation therapy after
autologous hematopoietic stem cell transplantation in
patients with newly diagnosed multiple myeloma
by Michele Cavo, Lucia Pantani, Maria Teresa Petrucci, Francesca Patriarca, Elena
Zamagni, Daniela Donnarumma, Claudia Crippa, Mario Boccadoro, Giulia Perrone,
Antonietta Falcone, Chiara Nozzoli, Renato Zambello, Luciano Masini, Anna Furlan,
Annamaria Brioli, Daniele Derudas, Stelvio Ballanti, Maria Laura Dessanti, Valerio
De Stefano, Angelo Michele Carella, Magda Marcatti, Andrea Nozza, Felicetto
Ferrara, Vincenzo Callea, Catello Califano, Annalisa Pezzi, Anna Baraldi, Mariella
Grasso, Pellegrino Musto, and Antonio Palumbo
Blood
Volume 120(1):9-19
July 5, 2012
©2012 by American Society of Hematology
CONSORT diagram of patient flow through the study.
Michele Cavo et al. Blood 2012;120:9-19
©2012 by American Society of Hematology
Analysis of outcomes from the start of consolidation therapy with VTD or TD. Kaplan-Meier
curves for TTP (A), PFS (B), and OS (C) from the landmark of starting consolidation therapy. *P
value according to log-rank test.
Michele Cavo et al. Blood 2012;120:9-19
©2012 by American Society of Hematology
Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy.
Michele Cavo et al. Blood 2012;120:9-19
©2012 by American Society of Hematology
Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy according to
the presence or absence of cytogenetic abnormalities.
Michele Cavo et al. Blood 2012;120:9-19
©2012 by American Society of Hematology
Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy according to
t(4;14) positivity or negativity.
Michele Cavo et al. Blood 2012;120:9-19
©2012 by American Society of Hematology